Forskolin/rolipram - Innomedica

Drug Profile

Forskolin/rolipram - Innomedica

Alternative Names: Rolipram/forskolin; TLFR

Latest Information Update: 22 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator InnoMedica
  • Developer InnoMedica; University of Hawaii
  • Class Antihyperlipidaemics
  • Mechanism of Action Adenylate cyclase stimulants; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Suspended Atherosclerosis

Most Recent Events

  • 22 May 2017 Suspended - Preclinical for Atherosclerosis in Switzerland (Liposomal) (InnoMedica communication, May 2017)
  • 11 May 2017 Chemical structure information added
  • 12 Dec 2015 Preclinical trials in Atherosclerosis in Switzerland (Liposomal) (Innomedica pipeline, April 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top